Compare Kraft Heinz Co (KHC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Viatris Inc — how do they compare? Kraft Heinz Co trades at $24.7 (market cap $29.56B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays the higher dividend (6.42%). Which is the better fit depends on your goals.
| KHC | VTRS | |
|---|---|---|
Market Cap | $29.56B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $28.06 | $17.86 |
52-Week Low | $21.21 | $9.49 |
Enterprise Value | $45.88B | $30.81B |
Dividend Yield | 6.42% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
